Aveanna Healthcare (AVAH) Financials

Aveanna Healthcare’s recent results show continued revenue growth and a significant improvement in profitability compared with 2022 and 2023. Q2 2026 revenue reached $670.5 million, up 51.5% from $443.0 million in Q2 2022 and 13.7% from $589.6 million in Q2 2025. Revenue also increased 3.5% sequentially from Q1 2026.

Profitability has improved substantially from the large impairment-driven losses reported in 2022 and 2023. Q2 2026 operating income was $80.0 million, representing an 11.9% operating margin, while net income was $40.3 million, or $0.18 per diluted share. However, the company remains highly leveraged and used significant cash for an acquisition during the latest quarter.

• Strong multiyear revenue expansion: Quarterly revenue increased from $451.1 million in Q4 2022 to $670.5 million in Q2 2026. The comparable Q2 periods show particularly consistent growth, rising from $443.0 million in 2022 to $670.5 million in 2026.
• Improved operating profitability: Operating income improved from a $456.4 million loss in Q2 2022, which included a $470.2 million impairment charge, to $80.0 million of income in Q2 2026. Operating income also increased 15.4% from Q1 2026.
• Net income has remained positive in recent quarters: Aveanna reported net income of $5.2 million in Q1 2025, $27.0 million in Q2 2025, $178.8 million in Q4 2025, $41.7 million in Q1 2026 and $40.3 million in Q2 2026. The Q4 figure benefited from an unusually large tax benefit, so the more recent quarterly results provide a better indication of ongoing performance.
• Gross profit remains substantial: Q2 2026 gross profit was $218.5 million, up 3.8% from Q1 2026. The gross margin was approximately 32.6%, below Q2 2025’s 35.8% but well above the roughly 29% to 30% margins reported in several 2022 and 2023 quarters.
• Operating cash flow turned considerably stronger in Q2 2026: Cash flow from operations increased to $80.9 million from just $4.3 million in Q1 2026 and $51.6 million in Q2 2025. The improvement was driven partly by a $27.3 million benefit from changes in operating assets and liabilities.
• Shareholders’ equity has recovered: Total equity increased to $287.3 million at the end of Q2 2026 from $240.1 million in Q1 2026. Aveanna had negative equity in the comparable 2024 and early 2025 periods, making the recent return to positive equity a meaningful balance-sheet improvement.
• Liquidity remains positive but narrowed: Cash and equivalents were $97.2 million at the end of Q2 2026, compared with $189.3 million at the end of Q1. Current assets of $478.1 million exceeded current liabilities of $411.3 million, producing a current ratio of approximately 1.16.
• Accounts receivable continues to grow with revenue: Accounts receivable reached $337.2 million in Q2 2026, up from $316.3 million in Q2 2025. This growth is consistent with higher sales, but investors should monitor collections and working-capital requirements because receivables represent the majority of current assets excluding cash.
• Acquisition spending sharply reduced cash: Aveanna spent $169.4 million on acquisitions and $1.3 million on property and equipment in Q2 2026. As a result, investing cash flow was negative $175.4 million and total cash declined by $92.1 million during the quarter despite strong operating cash generation.
• Debt and interest costs remain significant: Total short- and long-term debt was approximately $1.30 billion at the end of Q2 2026. The company reported $27.8 million of interest expense and paid $27.0 million of cash interest during the quarter, which continues to limit the conversion of operating income into net income and free cash flow.
• Balance-sheet assets are heavily concentrated in goodwill: Goodwill totaled $1.28 billion, or roughly 61% of total assets, at the end of Q2 2026. This concentration increases the importance of future acquisition performance and leaves the company exposed to potential impairment charges if acquired businesses underperform.
• Share dilution has been a persistent concern: Weighted-average diluted shares increased from 185.6 million in Q4 2022 to 224.9 million in Q2 2026. Shares also rose from 222.1 million in Q1 2026 to 224.9 million in Q2, which can reduce per-share benefits from earnings growth.

Overall, Aveanna’s financial statements point to a healthier operating business, with strong revenue growth, positive earnings and improved operating cash flow. The key risks are the company’s high debt burden, sizable interest expense, acquisition-related cash usage and continued share dilution. Investors should focus on whether future acquisitions generate enough cash to support debt reduction while preserving the recent improvement in operating margins.